Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Geron Corporation (GERN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies, Geron uses its SEC reports to detail financial performance, material events, clinical progress and corporate actions related to its telomerase inhibitor RYTELO (imetelstat) and broader business.
Investors can review current reports on Form 8-K that Geron has filed in connection with key developments. Recent 8-K filings have addressed topics such as quarterly financial results and business highlights, 2026 financial guidance for RYTELO net product revenue and total operating expenses, a strategic restructuring plan including a reduction in workforce, executive leadership changes, and amendments to compensation and inducement award plans. These filings provide formal context for press releases and outline the board-approved actions and estimated financial impacts of restructuring and other initiatives.
In addition to 8-Ks, Geron’s periodic reports on Forms 10-K and 10-Q (accessible through EDGAR and summarized on this page when available) typically include detailed financial statements, discussion of revenue sources, risk factors, clinical program descriptions and capital structure information. For a company like Geron, these filings are central to understanding how RYTELO product revenue, license fees and royalties fit within its overall operating results and cash position.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, updates on the IMpactMF Phase 3 trial in myelofibrosis, or the scope and cost of restructuring plans. Users can quickly identify important disclosures without reading every line of the underlying documents. The platform also surfaces insider and equity-related information reported in connection with inducement grants and executive compensation arrangements, helping investors monitor how management and employees are incentivized.
Because Geron’s strategy depends on clinical and commercial execution in hematology-oncology, its SEC filings are a primary source for tracking progress, risks and governance decisions. This page brings together those documents and AI-driven insights so that investors can efficiently evaluate GERN’s regulatory history and ongoing obligations.
Geron Corporation furnished an update outlining its financial outlook and investor communications for 2026. The company issued a press release with 2026 financial guidance, including expected RYTELO® net product revenue and total operating expenses for the year. This gives the market a view of how management currently sees revenue from its RYTELO franchise and the cost base needed to support the business.
Geron also provided a January 2026 corporate slide presentation that will be used in meetings with analysts and investors during the 44th Annual J.P. Morgan Healthcare Conference. Both the press release and the slides are furnished as exhibits rather than filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced.
Geron Corporation amended its existing Pharmakon-backed loan facility to extend key dates while keeping core terms the same. The 5-year senior secured term loan totals up to $250.0 million, split into a funded $125.0 million Tranche A, a $75.0 million Tranche B available at the company’s option subject to limited conditions, and a $50.0 million Tranche C that becomes available once a specified trailing twelve-month RYTELO™ revenue milestone is reached.
The amendment moves the outside date for drawing Tranche B and, once available, Tranche C from December 31, 2025 to July 30, 2026, giving Geron more time to access these funds. It also pushes the Makewhole Date, used to calculate early prepayment charges, from November 1, 2026 to May 1, 2027, while leaving the existing prepayment premium schedule and other loan terms unchanged.
Geron Corporation is implementing a strategic restructuring plan that includes reducing its workforce by about one-third from approximately 260 employees and expects about $18 million in restructuring and related charges. The board unanimously approved the plan on December 10, 2025, and the company began notifying affected employees on December 16, 2025, with the reduction expected to be substantially complete in the first quarter of 2026.
The charges, driven mainly by one-time severance, healthcare and related employee costs, are expected to affect results in the fourth quarter of 2025 and first quarter of 2026, with most cash payments occurring through the first quarter of 2026. Geron states the charges are not currently expected to include non-cash equity-based compensation and notes that actual costs, timing, and the business impact of the plan could differ materially from its estimates.
Geron Corporation reported Q3 2025 results, showing continued commercialization of RYTELO. Total revenues were $47.3 million, driven by net product revenue of $47.2 million. The company recorded a net loss of $18.4 million (basic and diluted loss per share of $0.03), narrowing from the prior year period.
Operating expenses reflected commercial scale-up: cost of goods sold were $1.0 million, research and development $21.1 million, and selling, general and administrative $39.0 million. As of September 30, 2025, Geron held $421.5 million in cash, cash equivalents, restricted cash and marketable securities, with inventory of $95.4 million supporting RYTELO supply. Noncurrent debt was $119.3 million, and stockholders’ equity stood at $248.7 million. Interest expense rose to $8.6 million in the quarter, reflecting financing costs alongside growing product sales.
Geron Corporation (GERN) filed a current report announcing it issued a press release with financial results for the quarter ended September 30, 2025 and recent business highlights. The press release is provided as Exhibit 99.1 and dated November 5, 2025.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and therefore is not subject to Section 18 liabilities and is not incorporated by reference into other filings.
Geron Corporation (GERN) reported an insider equity award. On 10/20/2025, the company granted its EVP, Chief Commercial Officer a stock option covering 3,000,000 shares of common stock at an exercise price of $1.27 per share, recorded at a grant price of $0 for the derivative security.
The option expires on 10/19/2035. Vesting is scheduled as follows: 375,000 shares vest on April 20, 2026; the remaining 2,625,000 shares vest in 42 equal monthly installments commencing April 20, 2026, contingent on continued service. The filing indicates direct ownership of the derivative securities following the grant.
Geron Corporation (GERN) executive Ahmed ElNawawi filed a Form 3 initial statement of beneficial ownership. The filing reports 10,000 shares of common stock beneficially owned directly.
ElNawawi serves as EVP, Chief Commercial Officer. The date of the event requiring the statement is 10/20/2025. Table II shows no derivative securities listed in this filing.
Geron Corporation announced leadership changes. On October 10, 2025, director Gaurav Aggarwal, M.D. resigned from the Board, effective immediately, citing professional obligations; the company stated his decision was not due to any disagreement on operations, policies, or practices. Also on October 10, V. Bryan Lawlis, Ph.D. informed the Board he will not stand for re‑election at the 2026 Annual Meeting and will serve until his term ends.
Effective October 15, 2025, Andrew J. Grethlein, Ph.D., Executive Vice President, Chief Operating Officer, and Jim Ziegler, Executive Vice President, Chief Commercial Officer, will depart. Each is eligible for severance benefits under existing employment agreements as described in the company’s April 8, 2025 proxy. To support transition, Dr. Grethlein entered a consulting agreement effective October 16, 2025 for up to 12 months at a specified hourly rate with a monthly hour cap. On October 13, 2025, the company issued a press release on four executive leadership transitions and appointments (Exhibit 99.1).
Geron Corp director Robert J. Spiegel received 5,702 shares of common stock as payment for his quarterly board and committee fees. The shares were issued on 09/30/2025 and priced at $1.37 per share, based on the closing price that day. After the issuance, Spiegel beneficially owns 188,546 shares. The Form 4 was signed by an attorney-in-fact on 10/01/2025. This disclosure reflects a routine non-derivative compensation issuance to a director and reports the resulting direct ownership level.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin jointly report beneficial ownership of 43,000,000 shares of Geron Corp common stock, equal to 6.75% of the outstanding class. The filing shows the reporting persons hold shared voting and shared dispositive power and report no sole voting or dispositive power.
The ownership percentage is calculated using 636,917,758 shares outstanding per Geron's 10-Q; the filers certify the shares were not acquired to change or influence control and include a joint filing statement assigning responsibility for future amendments.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
